Table 1 Baseline patient characteristics
From: CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
Characteristic | Total patient cohort | Patients with baseline CA19-9 | Patients with pre- and post-treatment CA19-9 |
|---|---|---|---|
n | 218 | 154 | 88 |
Median age (range) (years) | 63 (28–86) | 63 (28–86) | 63 (42–86) |
Male (%) | 62.8 | 63.6 | 62.5 |
Disease extent (%) | |||
Metastatic | 62.8 | 66.2 | 64.7 |
Locally advanced | 37.2 | 33.8 | 35.3 |
Performance status (%) | |||
0 | 12.8 | 12.9 | 17.0 |
1 | 56.9 | 62.3 | 62.5 |
2 | 25.7 | 24.7 | 20.5 |
3 | 0.9 | — | — |
Not documented | 3.7 | — | — |
Chemotherapy received (%) | |||
None | 4 | 0 | 0 |
PVI 5FU | 48 | 51 | 45.5 |
PVI 5FU+MMC | 33 | 28 | 21.6 |
GEM | 6 | 8.5 | 19.4 |
GEM+CAP | 9 | 12.5 | 12.5 |
Other | 0 | 0 | 1 |
